Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)

Wells Fargo analyst Derek Archila reiterated an Overweight rating and $32.00 price target on Nurix (NASDAQ: NRIX)

The analyst comments "Thoughts on the stock. Shares are up +146% vs XBI's +10% YTD. While there is decent value priced in for NX-5948's oppty in CLL post EHA, we think the data updates into YE24 will offer incremental upside to this, particularly as more investors assign credit for NX-5948 in NHL and I&I indications. Neither of these are full appreciated at these levels. Looking ahead, clarity on NX-5948's regulatory path in 2025 for CLL will also be a positive for shares."

For an analyst ratings summary and ratings history on Nurix click here. For more ratings news on Nurix click here.

Shares of Nurix closed at $25.16 yesterday.

You May Also Be Interested In

• JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
• Brown & Brown (BRO) Misses Q3 EPS by 2c
• Virgin Galactic's lead Delta class spaceship to arrive Oct. 28